

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GenFleet Therapeutics (Shanghai) Inc.

劲方医药科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2595)

VOLUNTARY ANNOUNCEMENT

Statement on the Proprietary Intellectual Property Status of GFH276, a Pan RAS (ON) Inhibitor

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the “**Company**” or “**GenFleet**”) on a voluntary basis.

The Company has recently noted certain reports concerning that Revolution Medicines Inc. (“**RevMed**”) issued correspondence to a third-party entity regarding patent and trade secret disputes on RAS inhibitors.

The Company hereby clarifies and emphasizes that all entities, products or disputed matters referenced in RevMed’s correspondence are entirely unrelated to the Company. GenFleet’s Pan RAS inhibitor GFH276 is developed on fully independent, original and proprietary intellectual property, with no exposure to risks of aforementioned infringement or trade secret disputes.

GenFleet has established an extensive global patent portfolio for the Pan RAS inhibitor program: the core patent covering GFH276’s compound structure was officially published on March 6, 2025, with its protection period projected to extend until 2044.

About GFH276

GFH276 is an oral novel small-molecule Pan RAS (ON) inhibitor hijacking Cyp A to target active, GTP bound RAS proteins of most wild/mutant subtypes, including most commonly found KRAS mutant (G12C, G12D, G12V, etc.) proteins. Preclinical research of GFH276 demonstrates dose-dependent anti-tumor activity and drives tumor regression in multiple KRAS mutant tumor models. GFH276 also holds the potential to

outperform the mainstream SIIP (switch II pocket)-based KRAS inhibitors in overcoming adaptive and acquired resistance.

Forward-looking Statements

Specific information in this announcement may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as “predict”, “believe”, “plan”, “forecast”, “expect”, “will”, “may”, “should” and other words of similar meanings. Based on the management’s current beliefs, plans, estimates and expectations of the Company’s operation and market trends subject to changes beyond control, the forward-looking terminology reflects the Company’s beliefs, plans, estimates and expectations of future development. Actual outcome in the future may differ significantly from forward-looking words owing to market, policy, and R&D uncertainties, among others. Subject to the above-mentioned uncertainties, the Company makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of this presentation, and you are cautioned not to solely rely on such forward-looking words. Neither the company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using this presentation. Investors are advised to exercise due diligence with reference to the company’s official disclosures for decision-making.

GLOSSARY OF TECHNICAL TERMS

“Cyp A”	cyclophilin A is a type of peptidyl prolyl cis-trans isomerase regulating protein folding and trafficking and is broadly expressed and abundant inside cells
“KRAS”	Kirsten RAS, a member of the RAS family of proteins
“Pan RAS”	active forms of RAS proteins across wild-type and mutant variants
“RAS”	ras sarcoma, a family of proteins that are critical regulators of cellular signaling pathways; it primarily includes HRAS, KRAS, and NRAS
“SIIP”	switch II pocket (SIIP) is an allosteric drug-binding pocket near the Switch II region of RAS proteins

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing

of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market GFH276 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, April 28, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors